Effect of Cytochrome P450 (CYP) 2D6 Genetic Polymorphism on the Inhibitory Action of Antidepressants on CYP2D6-Mediated Dopamine Formation from p-Tyramine.

PURPOSE The inhibitory effects of antidepressants, such as imipramine, desipramine, and fluvoxamine, on dopamine formation from p-tyramine catalyzed by cytochrome P450 (CYP) 2D6.2 (Arg296Cys, Ser486Thr) and CYP2D6.10 (Pro34Ser, Ser486Thr), were compared with those on dopamine formation catalyzed by CYP2D6.1 (wild type), to investigate the effect of a CYP2D6 polymorphism on neuroactive amine metabolism in the brain. METHODS Inhibition constants (Ki) of the antidepressants toward dopamine formation catalyzed by CYP2D6.1, CYP2D6.2, and CYP2D6.10, which were expressed in recombinant Escherichia coli, were compared. RESULTS Imipramine and desipramine competitively or non-competitively inhibited dopamine formation mediated by CYP2D6.1, CYP2D6.2, and CYP2D6.10 with Ki values of 3.9-4.9, 5.9-9.6, and 26.7-37.5 µM, respectively. The maximal velocity (Vmax) values for dopamine formation by all CYP2D6 variants gradually increased with increasing fluvoxamine concentrations up to 40-100 µM, indicating that fluvoxamine stimulated dopamine formation. CONCLUSIONS These results suggest that the inhibition/stimulation of CYP2D6-mediated dopamine formation by these antidepressants would be affected by CYP2D6 polymorphism in the brain. This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue's contents page.

[1]  Neil A. Miller,et al.  The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database , 2017, Clinical pharmacology and therapeutics.

[2]  T. Niwa,et al.  Effect of genetic polymorphism on the inhibition of dopamine formation from p-tyramine catalyzed by brain cytochrome P450 2D6. , 2017, Archives of biochemistry and biophysics.

[3]  H. Yamazaki,et al.  Regioselective hydroxylation of steroid hormones by human cytochromes P450 , 2015, Drug metabolism reviews.

[4]  M. Freeman,et al.  Pharmacotherapy for Mood Disorders in Pregnancy: A Review of Pharmacokinetic Changes and Clinical Recommendations for Therapeutic Drug Monitoring , 2014, Journal of clinical psychopharmacology.

[5]  H. Yamazaki,et al.  Comparison of catalytic properties of cytochromes P450 3A4 and 3A5 by molecular docking simulation. , 2013, Drug metabolism letters.

[6]  E. Bromek,et al.  Role of brain cytochrome P450 (CYP2D) in the metabolism of monoaminergic neurotransmitters , 2013, Pharmacological reports : PR.

[7]  H. Yamazaki,et al.  Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition. , 2011, Current drug metabolism.

[8]  T. Furukawa,et al.  Fluvoxamine versus other anti-depressive agents for depression. , 2010, The Cochrane database of systematic reviews.

[9]  H. Yamazaki,et al.  Heterotropic cooperativity in oxidation mediated by cytochrome p450. , 2008, Current drug metabolism.

[10]  S. Imaoka,et al.  Effect of psychotropic drugs on the 21-hydroxylation of neurosteroids, progesterone and allopregnanolone, catalyzed by rat CYP2D4 and human CYP2D6 in the brain. , 2008, Biological & pharmaceutical bulletin.

[11]  Barry C. Jones,et al.  DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS , 2004, Drug Metabolism and Disposition.

[12]  Y. Funae,et al.  Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. , 2004, Brain research. Molecular brain research.

[13]  Pal Pacher,et al.  Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? , 2004, Current pharmaceutical design.

[14]  S. Imaoka,et al.  Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain. , 2004, Endocrinology.

[15]  Nico P E Vermeulen,et al.  Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities. , 2003, Journal of medicinal chemistry.

[16]  A. Rettie,et al.  Expression, Purification, Biochemical Characterization, and Comparative Function of Human Cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 Allelic Isoforms , 2002, Journal of Pharmacology and Experimental Therapeutics.

[17]  Slobodan Petar Rendic.  Summary of information on human CYP enzymes: human P450 metabolism data , 2002, Drug metabolism reviews.

[18]  S. Imaoka,et al.  Progesterone oxidation by cytochrome P450 2D isoforms in the brain. , 2001, Endocrinology.

[19]  D. Figgitt,et al.  Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders. , 2000, Drugs.

[20]  J. Azuma,et al.  CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. , 2000, Pharmacogenetics.

[21]  K. Chiba,et al.  Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. , 2000, British journal of clinical pharmacology.

[22]  Y. Sugiyama,et al.  Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. , 1998, Pharmacological reviews.

[23]  S. Imaoka,et al.  Dopamine formation from tyramine by CYP2D6. , 1998, Biochemical and biophysical research communications.

[24]  S. Imaoka,et al.  Tissue distributions of CYP2D1, 2D2, 2D3 and 2D4 mRNA in rats detected by RT-PCR. , 1998, Biochimica et biophysica acta.

[25]  G. Murray,et al.  Regional distribution of individual forms of cytochrome P450 mRNA in normal adult human brain. , 1998, Biochemical pharmacology.

[26]  J. Lafitte,et al.  Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. , 1997, Pharmacogenetics.

[27]  M. Ingelman-Sundberg,et al.  Nomenclature for human CYP2D6 alleles. , 1996, Pharmacogenetics.

[28]  T Sakaki,et al.  Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. , 1996, Biochemical pharmacology.

[29]  M. Ingelman-Sundberg,et al.  Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. , 1994, Molecular pharmacology.

[30]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[31]  M. Komori.  A novel P450 expressed at the high level in rat brain. , 1993, Biochemical and biophysical research communications.

[32]  C. Alm,et al.  DEBRISOQUINE HYDROXYLATION POLYMORPHISM AND PERSONALITY , 1989, The Lancet.

[33]  B. Rozdilsky,et al.  Evidence for the presence of m-tyramine, p-tyramine, tryptamine, and phenylethylamine in the rat brain and several areas of the human brain. , 1978, Biological psychiatry.

[34]  R. Johansson,et al.  Plasma levels of imipramine and desipramine in man after different routes of administration , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[35]  Y. Funae,et al.  CYP2D in the brain. , 2003, Drug metabolism and pharmacokinetics.

[36]  Y. Sugiyama,et al.  Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. , 1998, Annual review of pharmacology and toxicology.

[37]  T Nakagawa,et al.  A pharmacokinetic analysis program (multi) for microcomputer. , 1981, Journal of pharmacobio-dynamics.